Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

BENEKLİ, MUSTAFA; YALÇIN, ŞUAYİB; ÖZKAN, METİN; ELKIRAN, EMİN; Sevinc, Alper; ÇABUK, DEVRİM; COŞKUN, HASAN; Oksuzoglu, Berna; Bayar, Banu; Akbulat, Akif; Ozet, Ahmet

doi:10.2147/ott.s70670

Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

BENEKLİ M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T., Sevinc A., ÇABUK D., ...Daha Fazla

ONCOTARGETS AND THERAPY, cilt.8, ss.1-5, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 8
Basım Tarihi: 2015
Doi Numarası: 10.2147/ott.s70670
Dergi Adı: ONCOTARGETS AND THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1-5
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication.